Identifying the Sentinel Lymph Node in Patients with Cutaneous Melanoma - Preliminary Report of a Private Clinic in Bucharest

Bobircă, Florin; Coltoiu, Casandra; Jauca, Cristina; Tebeică, Tiberiu; Bobircă, Anca; Pumnea, Adela; Leventer, Mihaela

doi:10.21614/chirurgia.115.4.476

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that HIF-1 α has both beneficial and detrimental effects in chronic kidney disease [ 16 , 17 ]. The pharmacological action of roxadustat is to increase HIF-1 α expression by mimicking hypoxia in vivo and inhibiting prolyl hydroxylase [ 18 ]. This study aimed to observe the influence of roxadustat on factors associated with renal fibrosis in the blood of patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of Roxadustat on Factors Associated with Renal Fibrosis and Efficacy

Zheng

Zhang

Zhao

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. We investigated the effect of roxadustat on factors associated with renal fibrosis and efficacy. Methods. Sixty patients meeting the inclusion criteria between January 2021 and October 2021 were equally distributed into observation (roxadustat) group and control (Erythropoietin) group. Then, the expression of serum hypoxia-inducible factor 1-alpha (HIF-1α), transforming growth factor-β (TGF-β1), vascular endothelial growth factor (VEGF), fibronectin (FN), and collagen Ⅳ (C-IV) was compared at different time points (baseline, 2-week follow-up, and 4-week follow-up). The improvement degree of hemoglobin (Hb) and the change level of iron parameters and hepcidin were also compared between the two groups. Results. In the roxadustat group, the expression of HIF-1α at 2 weeks was significantly higher than the baseline and approached the baseline value at 4 weeks. At 4 weeks, TGF-β1 and FN expression was significantly lower than baseline. In addition, the improvement of Hb in the roxadustat group was significantly higher than that in the control group at 4 weeks, and the change of ferritin, transferrin, and hepcidin indexes from baseline was better than in the control group. Conclusion. After giving roxadustat, it can change the expression of HIF-1α, TGF-β1, and FN. Its efficacy is superior to EPO, which is worthy of clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%